<DOC>
	<DOCNO>NCT01365572</DOCNO>
	<brief_summary>The purpose study evaluate feasibility , safety , effectiveness EndeavorTM ResoluteTM Xience VTM stent implantation patient restenosis follow drug-eluting stent ( DES ) implantation . The investigator evaluate clinical , angiographic intravascular ultrasound ( IVUS ) assessment 9-month efficacy EndeavorTM ResoluteTM Xience VTM implantation DES restenosis ass vascular change re-treatment DES DES restenosis use follow-up IVUS analysis . In addition , investigator evaluate effectiveness retreatment EndeavorTM ResoluteTM Xience VTM stent implantation patient restenosis DES</brief_summary>
	<brief_title>New Generation Drug Eluting Stent In-stent Restenosis Drug Eluting Stent ( RESTENT-ISR Trial )</brief_title>
	<detailed_description />
	<criteria>Instent restenosis ( 50 % quantitative angiographic analysis ) follow type DES ; insegment restenotic lesion without ISR include Evidence myocardial ischemia due restenosis ( e.g. , stable , unstable angina , recent infarction , silent ischemia , positive functional study reversible change ECG without ischemia ) 70 % quantitative angiographic analysis Repeat revascularization , need another stent ( single stent implant lesion , lesion length 28mm ) IVUS available lesion Nonemergent condition Patients confirm study enrollment 9 month followup angiogram IVUS Lesion &amp; Procedural exclusion criterion IVUS unavailable lesion Restenotic lesion follow PCI de novo lesion like ; leave main lesion BMS restenotic lesion vein graft lesion Restenotic lesion follow 2.25mm DES implantation Prior history repeat DES implantation DES restenosis ( conventional cut ballooning treatment DES restenosis include study ) Simultaneous implantation different type DES restenotic another de novo lesion ( Only DES implantation allow restenotic another de novo lesion ) Patients little possibility perform followup angiogram IVUS General exclusion criterion Contraindication antiplatelet agent &amp; Bleeding history within prior 3 month Prior history current presentation DES thrombosis Age 80 year Known hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , Zotarolimus , Everolimus Severe hepatic dysfunction ( 3 time normal reference value ) Serum creatinine level 2.0 mg/dL endstage renal disease dialysis LVEF le 30 % Pregnant woman woman potential childbearing An elective surgical procedure plan would necessitate interruption clopidogrel first 9 month Life expectancy 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Drug-eluting stent</keyword>
</DOC>